Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.

By C. Ribic, D. Sargent, M. Moore, S. Thibodeau, A. French, R. Goldberg, S. Hamilton, P. Laurent-Puig, R. Gryfe, L. Shepherd and 3 more. New England Journal of Medicine, 2003

2,144 citations recorded by the source corpus.

Subfields: Computer Networks and Communications, Hardware and Architecture

View Paper: https://www.semanticscholar.org/paper/bcf6127a8544f82d575676e1c33b108bf3f631df

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. E. Cutsem
2. L. Diaz
3. J. Tie
4. G. Argilés
5. C. Tomasetti
6. S. Kopetz
7. H. Schmoll
8. H. Lynch

Citations in the corpus

• Microsatellite instability in colorectal cancer—the stable evidence (2010, background): “These features can be successfully combined to predict the likelihood of the presence of MSI in tumor samples”
• Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. (2010, methodology): “Our findings in the independent data set assembled for this projectareconsistentandsupportiveof thefindingsofRibicetal.(20) MMR”
• ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. (2012, background): “• Pooled analyses have suggested a detrimental effect for adjuvant treatment with 5-fluorouracil (5-FU) in patients with stage II MSI-H/dMMR tumours, what could not be confirmed by recent analyses from randomized trials (PETACC 3, QUASAR) [18, 31–33].”
• Impact of BRAF Mutation and Microsatellite Instability on the Pattern of Metastatic Spread and Prognosis in Metastatic Colorectal Cancer (2011, background): “Colorectal cancer (CRC) is the third most common cancer and most frequent cause of cancer death worldwide.1 Over the past decade, there has been considerable progress in the systemic treatment of CRC. Median survival for metastatic CRC has improved from 10 months to >20 months with the development o”
• Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications (2009, methodology): “In addition to its use in screening for LS, MSI testing is important because MSI-H is associated with a better clinical prognosis overall and stagefor-stage (58), and it predicts a relatively worse response to adjuvant chemotherapy for both stage II and III CRCs (59).”
• Microsatellite Instability as a Biomarker for PD-1 Blockade (2016, result): “AlthoughMSSpatients showedabenefit from5-FU treatment,MSI patients did not (46), a finding confirmed in smaller follow-up MSI Frequency in Cancer”
• Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer (2016, background): “S tus in the tumor defines a low-risk group in which adjuvant chemotherapy is not beneficial (6, 7).”
• Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. (2020, background): “In particular, MSI/MMR may be useful to identify a small (10%–15%) subset of stage II patients who are at a very low risk of recurrence and in whom the benefits of fluoropyrimidines have not been demonstrated and thus adjuvant chemotherapy should not be indicated [I, A] [51-55].”